PlushCare is a technology company.
PlushCare has raised $23.6M across 3 funding rounds.
PlushCare has raised $23.6M in total across 3 funding rounds.
PlushCare has raised $23.6M in total across 3 funding rounds.
PlushCare's investors include Baird Capital, Bessemer Venture Partners, High Alpha, MassMutual Ventures, Menlo Ventures, Notable Capital, Aux21 Capital, Catapult Capital, Daffy, Keshif Ventures, Mayfield, Moonshots Capital.
PlushCare is a telemedicine platform providing virtual primary care, urgent care, mental health services, and prescription management to patients across all 50 U.S. states.[1][2][4] It serves individuals and families seeking convenient, affordable healthcare without physical visits, solving issues like access barriers, long wait times, and high costs by enabling same-day video appointments with board-certified doctors from top U.S. medical schools.[1][4][5] Operating on a platform-to-consumer (P2C) model, it partners with independent licensed providers rather than employing them or owning clinics, and offers membership perks like unlimited messaging and prescription discounts.[1][5] Acquired by Accolade in 2021 for $450 million after raising $31 million, PlushCare has scaled nationwide with strong growth in telehealth demand.[1][2]
PlushCare was founded in 2014 in San Francisco by Dr. James Wantuck, a physician frustrated with the clogged healthcare system, and Ryan McQuaid, who experienced long waits as a patient.[1][4] The idea emerged from Wantuck's insight into inefficiencies and McQuaid's personal pain points, leading to the first product: a mobile app for booking video doctor appointments.[1][4] Early operations were bootstrapped from a back room in a San Francisco doctor's office, where Wantuck treated patients virtually while McQuaid handled bookings by phone.[4] Pivotal traction came through five funding rounds totaling $31 million, partnerships with top physicians, and expansion to comprehensive services, culminating in the 2021 acquisition by Accolade, which boosted its nationwide presence.[1][2]
PlushCare rides the telemedicine boom accelerated by COVID-19, addressing primary care shortages where millions lack doctors, reducing costs via early intervention and virtual delivery.[3][6] Its timing aligns with rising demand for on-demand health tech, as consumers prioritize convenience amid hybrid work and aging populations, while market forces like insurance integrations and FDA-approved remote prescribing favor scalable platforms.[1][5][6] By influencing the ecosystem, PlushCare sets standards for P2C models—partnering with independents for flexibility—and post-acquisition by Accolade, enhances enterprise health navigation, competing with peers like Ro and 98point6 in a $100B+ digital health market.[1][2]
PlushCare's integration with Accolade positions it for deeper enterprise adoption, expanding into menopause care and AI-driven personalization amid telehealth's projected 20%+ CAGR.[2] Trends like value-based care, regulatory tailwinds for virtual prescriptions, and multimodal services (e.g., labs-at-home) will propel growth, potentially evolving its influence toward holistic health ecosystems. As a pioneer in accessible virtual primary care, PlushCare exemplifies how telemedicine transforms barriers into everyday convenience, sustaining its mission in an increasingly digital health landscape.[1][4]
PlushCare has raised $23.6M across 3 funding rounds. Most recently, it raised $23.0M Series B in June 2020.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jun 1, 2020 | $23.0M Series B | Baird Capital, Bessemer Venture Partners, High Alpha, MassMutual Ventures, Menlo Ventures, Notable Capital | |
| May 1, 2020 | $520K Series B | Aux21 Capital, Catapult Capital, Daffy, Keshif Ventures, Mayfield, Moonshots Capital, Science, Sweet Capital, Zeev Capital | |
| Nov 1, 2016 | $63K Series A | Vasudev Bailey, Aux21 Capital, Baird Capital, Bessemer Venture Partners, Catapult Capital, Daffy, High Alpha, Highland Capital Partners, Hoxton Ventures, Keshif Ventures, MassMutual Ventures, Mayfield, Menlo Ventures, Moonshots Capital, Jeff Richards, Notable Capital, Pieter Kemps, Questa Capital, Radical Ventures, Science, Sweet Capital, The House Fund, What If Ventures, Zeev Capital, Michael Baum |